Ignite Creation Date:
2024-05-19 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06413745
Status:
RECRUITING
Last Update Posted:
2024-07-08
First Post:
2024-05-09
Brief Title:
Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
Sponsor:
Jiangsu HengRui Medicine Co Ltd
Organization:
Jiangsu HengRui Medicine Co Ltd
Study Overview
Official Title:
A Phase II Clinical Study of SHR-A1811 in Patients With HER2-expressingAmplified Locally Advanced Unresectable or Metastatic Biliary Tract Cancer BTC Who Have Previously Failed First or Second-line Systemic Therapy
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study was to evaluate the efficacy and safety of SHR-A1811 in patients with locally advanced unresectable or recurrent metastatic BTC with HER2 expression amplification who failed first-line or second-line systemic treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None